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Autoantibodies to myelin oligodendrocytes glycoprotein (MOG) are found in a fraction of
patients with inflammatory demyelination and are detected with MOG-transfected cells.
While the prototype anti-MOG mAb 8-18C5 and polyclonal anti-MOG responses from
different mouse strains largely recognize the FG loop of MOG, the human anti-MOG
response is more heterogeneous and human MOG-Abs recognizing different epitopes
were found to be pathogenic. The aim of this study was to get further insight into details
of antigen-recognition by human MOG-Abs focusing on the impact of glycosylation.
MOG has one known N-glycosylation site at N31 located in the BC loop linking two
beta-sheets. We compared the reactivity to wild type MOG with that toward two
different mutants in which the neutral asparagine of N31 was mutated to negatively
charged aspartate or to the neutral alanine. We found that around 60% of all patients
(16/27) showed an altered reactivity to one or both of the mutations. We noted seven
different patterns of recognition of the two glycosylation-deficient mutants by different
patients. The introduced negative charge at N31 enhanced recognition in some, but
reduced recognition in other patients. In 7/27 patients the neutral glycosylation-deficient
mutant was recognized stronger. The folding of the extracellular domain of MOG with
the formation of beta-sheets did not depend on its glycosylation as seen by circular
dichroism. We determined the glycan structure of MOG produced in HEK cells by
mass spectrometry. The most abundant glycoforms of MOG expressed in HEK cells are
diantennary, contain a core fucose, an antennary fucose, and are decorated with α2,6
linked Neu5Ac, while details of the glycoforms of MOG in myelin remain to be identified.
Together, we (1) increase the knowledge about heterogeneity of human autoantibodies
to MOG, (2) show that the BC loop affects recognition in about 60% of the patients,
(3) report that all patients recognized the unglycosylated protein backbone, while (4) in
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about 20% of the patients the attached sugar reduces autoantibody binding presumably
via steric hindrance. Thus, a neutral glycosylation-deficient mutant of MOG might
enhance the sensitivity to identify MOG-Abs.
Keywords: myelin oligodendrocyte glycoprotein (MOG), glycosylation, autoantibody recognition,
mass-spectrometry, demyelination
INTRODUCTION
Autoantibodies against myelin oligodendrocyte glycoprotein
(MOG) detected in cell-based assays occur in a proportion of
patients with inflammatory CNS diseases. High levels of such
autoantibodies were initially detected in pediatric patients (1–3),
then also in adults, and MOG-Abs are implicated in prognosis
and therapy optimization (4–11). MOG-Abs are assumed to be
pathogenic based on in vitro experiments (12–15) and injection
of total IgG from anti-MOG positive patients into experimental
animals (16–19). We have recently reported that affinity-purified
MOG-Abs from two patients who show cross-reactivity to rodent
MOG were pathogenic upon transfer into EAE animals by two
different mechanisms, namely by enhancing T cell activation of
cognate T cells and by inducing MS type II like demyelination
when the blood-brain barrier is breached (20).
MOG is exposed on the outside of intermodal myelin; the
crystal structure of the extracellular part of mouse (21) and
rat MOG (22) allowed the modeling of human MOG (23).
The antigen-binding fragment (Fab) of the prototype anti-MOG
mAb 8-18C5 was crystallized together with the extracellular
part of MOG and this revealed that the FG loop (aa101-
108) of MOG, which constitutes an IgV-like fold, makes the
dominant contribution to binding of this particular mAb (22).
A subsequent study showed that the amino acids His103 and
Ser104 are essential for binding of the mAb 8-18C5 and also
for the polyclonal anti-MOG IgG induced upon MOG DNA-
vaccination of BALB/c and SJL/J mice (24). In contrast to
these rodent models, the anti-MOG Abs in human patients
are more heterogeneous and most of the patients recognize
epitopes that are different from that of the prototype mAb 8-
18C5 (23). Also, the epitopes of MOG-Abs affinity-purified from
two patients were found to be pathogenic upon transfer into
rats and they differed in their fine-specificity from the mAb
8-18C5 (20).
The aim of this study was to get further insight into details
of antigen recognition of human autoantibodies against MOG.
Specifically, we analyzed here the impact of the glycosylation
site of MOG on antibody binding. In principal, glycosylation
of an antigen can have different, even opposing effects on
antibody binding. For example, recognition of contactin by
autoantibodies from 3/4 patients with chronic inflammatory
demyelinating polyneuropathy depended on specific contactin
N-glycosylation (25). In contrast, glycosylation of the Env-
protein of the immunodeficiency viruses HIV and SIV at
multiple sites blocks antibody binding and is an immune
evasion strategy of these viruses in infected individuals (26,
27). Now broadly neutralizing Abs to HIV are a therapeutic
perspective, but such Abs have to accommodate and avoid
glycans, while some of them recognize glycan-dependent
epitopes (28).
MOG has one N-linked glycosylation site, N31 (23). It was
previously observed that when this asparagine was mutated to
aspartate (N31D), the MOG-recognition of some patients was
altered (1, 23, 29). It was unclear, however, whether this altered
binding is due to the introduction of the negatively charged
aspartate or due to the abrogation of glycosylation. We addressed
this issue here by generating a neutral glycosylation deficient
mutant of MOG (N31A) and comparatively analyzed the anti-
MOG reactivity in a total of 27 anti-MOG positive patients to
wild type MOG and the different glycosylation-deficient variants
of MOG. Thereby we found that the different mutations of the
glycosylation site affect the antigen recognition in 15/27 patients
and noted seven different patterns of antigen-recognition of
variants of the glycosylation site. We applied mass spectrometry
to determine the glycoforms of MOG in HEK cells, because HEK
cells are the preferred expression system to analyse MOG-Abs in
cell based-assays (12, 30–33). Our data extend our knowledge
about the heterogeneity of human autoantibodies to MOG,
indicate that the glycosylation site affects antigen-binding in a
large proportion of patients and that the glycan attached to MOG
is a steric hindrance for antigen recognition in some patients.
MATERIALS AND METHODS
Patients
This study included sera of 27 adult patients with different
inflammatory CNS diseases and antibodies to cell-bound MOG
(Table 1).We give the original diagnosis inTable 1. It is currently
discussed whether patients with MOG-Abs constitute a separate
disease entity. Some of our patients had got the initial diagnosis
of MS, but typical MS patients do not have MOG-Abs (30).
Nevertheless, in many studies patients have been described who
met the diagnostic criteria of MS and were MOG-Ab positive
(4, 7, 10). These may be atypical cases or patients fulfilling
the criteria of MS, but with a specific phenotype (34), mostly
with a low intensity of anti-MOG reactivity. Informed consent
was obtained from each donor according to the Declaration of
Helsinki and the ethical committee of the medical faculty of the
LMU approved this study.
Molecular Cloning and Transfection
Full-length human MOG was subcloned into the pEGFP-
N1 plasmid (CLONTECH Laboratories, Mountain View, CA,
USA). This construct comprises a C-terminal enhanced GFP
(EGFP)-tag. Using the QuickChange Site-Directed Mutagenesis
Kit (Stratagene, Santa Clara, CA, USA), point mutations were
induced into MOG. The oligonucleotides used were: 5′-CAT
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TABLE 1 | Details of the anti-MOG positive patients.




3 MS/NMOSD Steroids + Teriflunomide
4 ADEM None
5 CIS None









15 Relapsing encephalomyelitis Steroids + Plasmapheresis
16 Relapsing ON None
17 Relapsing encephalomyelitis Azathioprine
18 Relapsing encephalomyelitis Steroids
19 MS Glatiramer acetate
20 NMOSD Azathioprine
21 NMOSD None
22 Relapsing ON Azathioprine
23 NMOSD Glatiramer acetate
24 Monophasic encephalitis None
25 Relapsing ON None
26 Relapsing ON None
27 NMOSD Steroids
aSome patients have been previously described in more detail: Patient 17 in Spadaro et al.
(29); patients 7 and 19 in Spadaro et al. (34), and patients 15, 16, 22, 23, 25, 26, and 27
in Spadaro et al. (20).
bWe give the original diagnosis; It is currently discussed whether patients with MOG-
Abs constitute a separate disease entity (8, 11, 35, 36). LETM, longitudinal extensive
transverse myelitis; NMOSD, neuromyelitis optica spectrum disorder; ADEM, acute
disseminated encephalomyelitis; CIS, clinically isolated syndrome; ON, optic neuritis;
RON, recurrent optic neuritis; BON, bilateral optic neuritis.
ATC TCC TGG GAA GGA CGC TAC AGG CAT GGA GG-
3′ (N31D) (23),5′-CAT ATC TCC TGG GAA GGC AGC TAC
AGG CAT GGA GG-3′ (N31A), and the corresponding reverse
complementary oligonucleotides. The sequences of the purified
plasmids were confirmed. HeLa cells were transfected transiently
using jetPRIME (Polyplus, Illkirch, France) according to the
instruction of the manufacturer, expressing MOG, N31D, or
N31A fused C-terminally to EGFP. Surface expression of each
of the MOG-constructs was confirmed by FACS-staining using
a recombinant version of the anti-MOG mAbs 8-18C5 with a
human IgG1 as Fc part (20, 37), which we call r8-18C5.
Determination of Reactivity to MOG
Variants in a Cell-Based Assay
For detection of serum antibodies, HeLa cells transiently
transfected with hMOG and its variants were suspended in
FACS buffer (1% FCS in PBS). The cells were incubated
with a 1:50 serum dilution or mAb r8-18C5 (0.5µg/ml) for
45min at 4◦C and washed three times in FACS buffer. The
cells were then incubated with a 1:500 dilution of a biotin-
SP conjugated goat anti-human IgG (Jackson ImmunoResearch,
West Grove, PA, USA) for 30min at 4◦C, washed three times,
and incubated with Alexa Fluor 647-conjugated streptavidin
(Jackson ImmunoResearch) at a dilution of 1:2000. Finally,
the cells were washed three times and suspended in a 1:2000
dilution of propidium iodide in PBS. Dead cells were excluded
by positive propidium iodide staining. For the determination
of anti-MOG reactivity, we gated on cells with a fluorescein
isothiocyanate fluorescence (FITC) intensity above 500 and
determined their mean channel fluorescence intensity (MFI) in
the allophycocyanin channel (APC). Cells transfected with the
mutants, wild type MOG, and with EGFP only were always
measured together in the same experiment. To quantify the
reactivity to the MOG variants, MFI ratio was calculated as
(MFI to the MOG variant-EGFP)/(MFI to EGFP). This MFI
ratio reflects properties of the autoantibodies, both amount
and affinity.
Deglycosylation
HeLa cells transfected with MOG-EGFP constructs were lysed
at 4◦C for 1 h in RIPA buffer (150mM NaCl, 1% NP-40, 0.5%
sodium deoxycholate, 50mM Tris pH8, 0.1% SDS) containing
complete protease inhibitor mixture (Roche Applied Science,
Penzberg, Germany). The lysate was then pelleted, and the
supernatant was analyzed. For deglycosylation, the supernatant
was digested with PNGaseF (New England Biolabs, Ipswich,
MA) in Glycoprotein Denaturing Buffer (New England Biolabs),
Glycobuffer 2 (New England Biolabs) and 1% NP40 (New
England Biolabs) at 37◦C overnight; Proteins (digested or
undigested) were analyzed by SDS-PAGE. The proteins were
electroblotted onto a PVDF membrane and detected by Western
blot with an anti-GFP-HRP conjugated antibody (Genetex,
Irvine, CA, USA) and developed using the Immobilon Western
kit used (Millipore, Burlington, MA, USA) and the Odyssey Fc
Imaging system (LI-COR, Bad Homburg, Germany).
Production of Recombinant MOG
We produced a recombinant version of the extracellular domain
(ECD) of human MOG (20) in HEK293-EBNA cells and
added at the C-terminus instead of the first transmembrane
region a HisTag and an AviTag using the pTT5 vector (38).
HEK293-EBNA cells were transfected, cultured under serum-
free conditions with the FreeStyle293 Expression Medium
(Thermo Fisher Scientific, Waltham, MA, USA). The secreted
ECD of MOG was purified with a His Trap HP column
(GE Healthcare, Uppsala, Sweden). With this expression
system we produced the ECD of the wild type MOG and a
glycosylation-deficient variant (T33N). Folding of the purified
proteins (0.2 mg/ml) was analyzed by circular dichroism
using a Jasco J-810 Spectropolarimeter (JASCO Corporation,
Tokyo, Japan). Data were corrected for the spectrum of the
buffer alone.
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Preparation of Ethyl Esterified Released
N-Glycans From Recombinant MOG
An SDS-PAGE gel band corresponding to HEK cell derived
MOG (15–20 µg, migrating at ∼21 kDa) was reduced, alkylated
and subsequently treated with N-glycosidase F (PNGase F;
Roche Diagnostics, Mannheim, Germany) to release the N-
glycans, as described previously (39). Additionally, 5 µg of
HEK derived MOG was denatured and incubated overnight
with PNGaseF in-solution at 37◦C (40, 41). Released N-glycans
were subjected to the selective ethyl esterification of sialic
acids, thereby introducing mass differences of +28.03 Da and
−18.01 Da for α2,6-linked N-acetylneuraminic and α2,3 N-
acetylneuraminic acid, respectively (40). Briefly, released glycans
were incubated with the derivatization reagent (250mM 1-
ethyl-3-(3-(dimethylamino)propyl)carbodiimide and 250mM 1-
hydroxybenzotriazole in ethanol) and incubated for 60min
at 37◦C. The derivatized glycans were enriched by cotton
hydrophilic-interaction liquid chromatography (HILIC)–solid-




MALDI-TOF-MS analysis was performed on an UltrafleXtreme
(Bruker Daltonics) operated under flexControl 3.3 (Build 108;
Bruker Daltonics). Two and 5 µL of the enriched ethyl esterified
glycans were spotted on a MALDI target (MTP AnchorChip
800/384 TF; Bruker Daltonics) together with 1 µL of super-DHB
(5 mg/mL in 50% ACN and 1mM NaOH). The spots were dried
by air at room temperature. For each spot, a mass spectrum was
recorded in the range fromm/z 1,000 to 5,000, combining 10,000
shots in a random walk pattern at 1,000Hz and 200 shots per
raster spot. Prior to the analysis of the samples, the instrument
was calibrated using a peptide calibration standard (Bruker
Daltonics). Tandem mass spectrometry (MALDI-TOF/TOF-
MS/MS) was performed for the most abundant glycans using
laser-induced dissociation, and compositions as well as structural
features of N-glycans were assessed on the basis of the observed
fragment ions.
Data Processing
For automated relative quantification of the released glycans, the
MALDI-TOF-MS files were converted to text files and analyzed
using MassyTools (version 0.1.8.1.) (43). Spectra were internally
calibrated using glycan peaks of known composition with a S/N
above nine, covering the m/z range of the glycans. Integration
was performed on selected peaks from all glycans that were
observed. For this, at least 95% of the theoretical isotopic pattern
was included. Several quality parameters were used to assess
the actual presence of a glycan i.e., the mass accuracy (between
−10 and 10 ppm), the deviation from the theoretical isotopic
pattern (below 25%) and the S/N (above three) of an integrated
signal. Analytes were included for relative quantification when
present in at least half of the technical replicates (excluding
poor quality spectra), resulting in a list of 58 glycans. Finally,
only glycans with an intensity covering at least 1% of the
FIGURE 1 | Folding of MOG does not depend on its glycosylation. The
extracellular domains of wild type MOG (black line) and an aglycosylated
variant (T33N; red line) were analyzed by circular dichroism. Both spectra have
a similar shape representing a predominant beta sheet conformation indicated
by the negative band at 213 nm. The differences around 230 and 200 nm are
probably due to the presence of the avi tag in the WT, which was absent in the
mutant. Protein concentration of WT and N31D was 0.1 mg/ml.
FIGURE 2 | N31A and N31D mutations completely abrogate MOG
glycosylation. Cell lysates of HeLa cells transiently transfected with the
mutants N31A, N31D, or wild-type MOG were digested with PNGase F as
indicated. Subsequently, proteins were separated by SDS gel, blotted and
developed with anti-GFP-HRP antibody. The bands represent the fusion
protein of MOG and EGFP.
overall glycan abundance were selected, resulting in 28 glycans
that were relatively quantified (as a fraction of the total glycan
signal intensity).
Statistics
We tested 27 anti-MOG positive patients with wild-type MOG
and two aglycosylated variants of MOG, N31A and N31D. Each
serum was tested with each MOG variant 4–5 times. A difference
between two MOG variants was considered significant if the
p-value was <0.05 of both the Quade omnibus-test and post-
hoc test and if the difference between the MFI ratios was >1.
Calculations were performed in R version 3.2.3. The Quade test
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FIGURE 3 | Seven patterns of anti-MOG reactivity in patients to N31A and N31D, but unaltered reactivity of r8-18C5. HeLa cells were transfected with EGFP alone
(closed gray graph), wild type MOG (black line), N31A (blue line), or N31D (red line). Depicted is the reactivity of r8-18C5 and of seven patients, who represent the
different pattern of anti-MOG reactivity (Table 2). One representative experiment of 4–5 replicates is shown. (A-H) Patterns of anti-MOG reactivity.
was chosen as non-parametric test for paired samples and more
than two groups. This test is recommended for our sample size.
The Friedman test gave almost identical results (data not shown).
RESULTS
Characterization of the Glycosylation
Deficient Mutants
We analyzed whether the confirmation of the ECD of MOG
depends on its glycosylation. To this end, we produced the ECD
of wild type MOG and a mutated variant that lacks glycosylation
reombinantly in HEK cells and analyzed these two proteins by
circular dichroism. This showed a similar formation of beta-
sheets indicating that the confirmation of MOG does not depend
on its glycosylation (Figure 1).
Lysates of cells transfected with wild type MOG or with the
mutants, N31A, and N31D, each fused to EGFP were treated
with PNGaseF. Cell lysates were separated by SDS-PAGE, blotted
and developed with anti-GFPmAb. Under the conditions chosen
for our study, wild type MOG and also both deglycosylated
forms ofMOG appeared only as amonomer (Figure 2). PNGaseF
treatment reduced the size of MOGwhile the sizes of the mutated
variants N31A and N31D were not changed (Figure 2). This
showed that N31A and N31D are not glycosylated and that N31
is the only N-linked glycosylation site used. To see, whether the
introduced mutations induced a gross alteration of MOG, both
mutants were analyzed for recognition by r8-18C5 using our cell-
based assay. We observed a similar expression and binding to
r8-18C5 (Figure 3A).
Heterogeneous Response to Two
Glycosylation Deficient MOG Mutants
We tested 27 anti-MOG positive patients (Table 1) with wild-
type MOG and two non-glycosylated variants of MOG, N31A,
and N31D. About 60% of these patients (16/27) reacted to at least
one of the two mutants differently than to the wild type MOG.
The raw data of the reactivity of each patient to each mutant are
given in Table 2 and FACS data for selected patients are shown
Figure 3.
We noted seven different patterns of reactivity toward
the different non-glycosylated variants of MOG (Table 2 and
Figure 3). In 11/27 patients we saw no significant difference in
recognition of these MOG mutants (example in Figure 3B). In
7/27 patients a higher reactivity to both non-glycosylated MOG
variants was observed. A closer look at the reactivity of these
seven patients showed a further diversity. Six of these seven
patients responded to the two mutants similarly (Figure 3C),
while another one had a higher reactivity to N31D than to
N31A (#15) (Figure 3D). In five other patients we noted a higher
reactivity to N31D than to wt MOG, while the reactivity to
N31A was not higher than to wt (Figure 3E). Two patients (#12
and #13) showed an increased recognition of N31D, but had
a reduced reactivity for the N31A (Figure 3F). An enhanced
reactivity to N31A, but a reduced one to N31D was observed
in one patient (#21) (Figure 3G). Patient #9 showed a reduced
reactivity to N31A (Figure 3H). Together, the reactivity to N31A
was higher in 8/27 and lower in 3/27 patients, while the reactivity
to N31D was higher in 14/27 and lower in only 1/27 patients.
Looking at individual patients, this study reveals an enormous
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TABLE 2 | Heterogeneous response to two glycosylation deficient MOG mutants.
Patient ID MFI ratio MOG MFI ratio N31A MFI ratio N31D p-value WT vs. N31A p-value WT vs. N31D p-value N31A vs. N31D
WT = N31A = N31D
2 6.0 7.4 5.6 0.506 0.506 1.000
4 29.0 34.2 32.9 0.506 0.506 1.000
6 211.2 164.3 199.9 0.297 1.000 0.297
10 142.4 138.3 168.5 0.574 0.083 0.188
16 187.2 225.0 211.1 0.622 0.203 0.399
18 3.7 3.9 4.6 0.390 0.060 0.214
20 5.7 7.7 7.7 0.049 0.058 0.910
23 3.7 3.6 4.4 0.064 0.039 0.003
25 97.5 114.4 117.6 0.058 0.049 0.910
26 132.5 103.9 133.7 0.161 0.781 0.108
27 77.5 86.7 121.2 0.897 0.227 0.190
WT < N31A = N31D
1 9.1 16.8 18.9 0.022 0.008 0.500
7 2.6 6.0 5.3 0.002 0.034 0.034
8 44.3 70.5 90.1 0.047 0.017 0.473
11 93.2 124.7 117.4 0.008 0.022 0.500
17 27.9 89.9 56.5 0.002 0.025 0.112
19 5.9 7.5 8.2 0.024 0.005 0.337
WT < N31A < N31D
15 9.8 13.9 47.4 0.034 0.002 0.034
WT = N31A < N31D
3 28.5 28.0 36.6 0.325 0.022 0.005
5 80.6 77.0 108.3 0.894 0.013 0.017
14 28.9 30.6 40.7 0.500 0.008 0.022
22 45.8 42.0 102.8 0.112 0.025 0.002
24 14.5 14.4 18.9 0.337 0.024 0.005
N31A < WT < N31D
12 38.8 31.4 70.1 0.034 0.034 0.002
13 94.2 65.7 102.1 0.034 0.034 0.002
WT < N31D < N31A
21 15.1 45.5 7.7 0.034 0.034 0.002
WT = N31D > N31A
9 26.1 20.9 27.5 0.042 0.625 0.019
Mean fluorescence intensity (MFI) ratios were calculated as described in materials and methods; values represent the arithmetic mean of 4–5 experiments. Highlighted in gray are values
considered significant. Patients (#20 and #25) had a p-value <0.05, but the response to the mutants was overall considered not significant since they did not pass the Omnibus test.
Also patients #7 and #23 had p-values <0.05, but also these responses were not considered significant, because their differences of the MFI ratios were <1.
heterogeneity of human autoantibodies to MOG with seven
different patterns of recognition uncovered by two mutations of
the glycosylation site.
Glycoforms of MOG
We performed in-gel and in-solution enzymatic release of N-
glycans from HEK derived MOG. The sialic acid stabilized N-
glycans were analyzed with MALDI-TOF-MS. A representative
MS spectrum is shown in Figure 4. To confirm our structural
assignment, we subjected several m/z values to tandem mass
spectrometry (MALDI-TOF/TOF-MS/MS, data not shown).
For example, this proved informative with regard to antenna
composition and fucosylation. Most spectra showed the presence
of a core fucose, where the precursor showed a loss of the
reducing end N-acetylglucosamine together with the fucose
(367.2 Da). Antenna fucosylation was observed on both
LacDiNAc and LacNAc antennae, resulting in the loss of
552.1 and 511.1 Da, respectively. Additionally, the presence of
LacDiNAc was confirmed by the specific fragment at m/z 429.3.
The MS/MS spectrum of the most abundant peak at m/z 2169.8
showed signal losses of 725.1 Da (LacDiNAc antenna carrying an
α2,6-linked sialic acid) and 684.3 Da (LacNAc antenna carrying
an α2,6-linked sialic acid). This indicated a mixture of two
isomers, with the sialic acid either on the LacDiNAc or LacNAc
antenna. In general, the presence of bisection of glycans could not
be excluded (indicated with the white squares in Figures 4, 5).
In total 28 glycans were selected for relative quantification
(Figure 5). Most N-glycans were diantennary, with mainly
LacNAc antennae as well as significant amounts of LacDiNAc
antennae. The major glycans were sialylated species with
predominantly 2,6-linked sialic acids. Most glycans showed core
fucosylation, with some indications of additional antennary
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FIGURE 4 | MALDI-TOF-MS spectrum of in-solution released N-glycans from recombinant MOG. Ions represent sodiated species ([M+Na]+). MALDI-TOF-MS
spectrum of in-solution released N-glycans from recombinant MOG. Ions represent sodiated species ([M+Na]+). The compositions of the major glycan peaks were
annotated based on the m/z values and information from tandem MS spectra (data not shown). Next to the proposed glycan structures schematically represented in
the figure, additional structural isomers may be present for many of the observed glycan compositions.
fucosylation. The glycan profiles obtained from in-solution and
in-gel glycan release were highly consistent and showed only
minor differences.
DISCUSSION
This study revealed that the glycosylation site of MOG influences
its recognition by autoantibodies in about 60% of patients.
We used two different glycosylation-deficient variants of MOG
(N31D and N31A) and found seven different patterns of
reactivity. While previous studies had noted that the N31D
mutant was stronger recognized by some patients (1, 23, 29, 34),
we now address the issue whether this is due to the introduced
negative charge or due to the loss of the sugar part. Our
study shows that both the negatively charged aspartate and the
missing sugar can affect antigen recognition, in a different way in
different patients.
Specifically, we noted that five patients showed a higher
reactivity to N31D, while the reactivity to N31A was the same
as to the wild type. In two other patients we observed a higher
reactivity to N31D, but a lower one to N31A. We conclude that
in these patients the introduced negative charge is responsible
for the enhanced binding to MOG rather than the absence of
the glycan.
In seven other patients, we observed a stronger reactivity to
both N31D and N31A. Six of these patients showed a similarly
enhanced reactivity to both mutants, while one recognized
N31D stronger than N31A. One further patient showed a higher
reactivity to N31A, but even a lower one to N31D. We conclude
that in these 7/27 patients with an enhanced reactivity to N31A
the glycan on MOG provides a hindrance for antibody binding,
reminding of the impact of the glycan shield of HIV and SIV
(26, 27). We then determined the glycan structure of MOG
produced in HEK cells by mass spectrometry and found that
the most abundant glycoforms are diantennary, contain a core
fucose, an antennary fucose and are decorated with α2,6 linked
Neu5Ac. Our findings indicate that this glycan structure can
provide a steric hindrance for antibody binding; this might
have implications for further improvement of cell-based assays
to detect MOG antibodies suggesting that the use of a neutral
glycosylation-deficient MOGmutant (like N31A) would enhance
the sensitivity to detect autoantibodies to MOG. In none of
the patients the reactivity to MOG depended on the glycan
structure, clearly different than it was described for recognition
of contactin (25).
Further, theMOG-reactivity of these patients is heterogeneous
concerning the impact of the negatively charged N31D. One
out of 27 patients showed a slightly lower reactivity to N31A,
but still a clear reactivity to this glycosylation-deficient mutant.
Thus, in this patient, the glycan on MOG might slightly enhance
its binding to the protein-backbone. Our observation that
the prototype anti-MOG r8-18C5 was not affected by any of
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FIGURE 5 | Relative abundance of recombinant MOG released N-glycans. In total, three spots from an in-gel digestion and four spots from an in-solution release
were analyzed. The graph shows the average relative abundances observed for 28 glycan species (normalized to the overall sum of intensities). Abbreviations used
are hexose (H), N-acetylhexosamine (N), fucose (F), and N-acetylneuraminic acid with either α2,3-linkage as indicated by lactonation (L) or α2,6-linkage as indicated
by esterification (E). Error bars, standard deviation.
the glycosylation deficient mutants is in accordance with the
previous reports (22, 23). Our identification of seven different
patterns of reactivity just using different mutations of the
glycosylation site extends the knowledge about heterogeneity of
MOG-epitopes recognized by patient antibodies.
While our experiments revealed the importance of the
glycosylation site for antibody recognition, details how the
glycan structure impacts antibody recognition remain to be
identified. This could be done by altering the glycan composition
by inducing or suppressing key glycosyltransferases. This may
tell whether tetra-antennary versus bi-antennary glycans or
differences e.g., in sialic acid linkage or branch fucosylation have
an impact on antibody recognition.
Those patients who show a different reactivity to N31D and/or
N31A might directly recognize the BC-loop of MOG, where the
N-linked glycosylation site is located (23), but we cannot exclude
that mutations of N31 of MOG have far-reaching effects on other
parts of MOG with an impact on antibody binding at a remote
side. An example for an alteration of protein-protein bindings
remote from the mutation site, is the recent observation that
a variant of alpha-1 antitrypsin at one side (aa213) affects the
interaction of a remote part of the molecule (aa143-153) with the
enzyme it inhibits, neutrophil elastase (44).
While this study elaborated the importance of the
glycosylation of MOG for antibody binding, also the
glycosylation of antibodies has major impact on their
biological activity, both on the effector functions and on
antigen-recognition. Glycosylation of the Fc-part of antibodies
regulates complement activation and FcR binding (45, 46) and
may serve as biomarker in autoimmunity (47). In multiple
sclerosis, IgG-Fc glycosylation is altered in the CSF and indicates
a pro-inflammatory pattern (48). Glycosylation of the Fab part of
Ig may enhance or reduce antigen binding (49).
Glycans regulate protein-protein interactions. In an intriguing
paper, glycosylation of MOG on myelin has been linked to
binding to DC-SIGN and a role for myelin glycosylation in
immune homeostasis of the healthy CNS was shown (50).
That study further showed that removal of fucose from
myelin reduced the DC-SIGN-dependent homeostatic control
of myelin (50). The glycosylation in a cultured cell line may
not reflect the native glycosylation of MOG in myelin. The
identification of the glycoforms of MOG in myelin may help
to identify binding partners of MOG. Whether MOG also
interacts with sialic acid binding proteins such as Siglecs (sialic
acid-binding immunoglobulin like lectins) (51) remains to
be analyzed.
Together, this study shows the importance of the glycosylation
site of MOG for binding of autoantibodies. Our finding that
the glycan provides a hindrance for antibody binding in
a proportion of patients has implications for development
of assays to enhance the sensitivity to detect antibodies
to MOG. Our observation of seven different patterns of
MOG-binding to glycosylation-deficient variants provides
further insight into details of antigen-recognition and
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extends the known heterogeneity of human autoantibodies
against MOG.
DATA AVAILABILITY
All datasets generated for this study are included in
the Manuscript.
ETHICS STATEMENT
Informed consent was obtained from each donor according to the
Declaration of Helsinki and the ethical committee of the medical
faculty of the LMU approveds this study.
AUTHOR CONTRIBUTIONS
IMF, CM, PH, AH, SW, AV, and FK performed experiments and
analyzed data. DJ, RH, MW, TK, and EM designed the study
and analyzed data. AK, LG, and TK provided clinical data and
analyzed data. MK performed statistical analysis. All authors
contributed to drafting of the manuscript.
FUNDING
This work was supported by the DFG (SFB TR128), the
Munich Cluster for Systems Neurology (ExC 1010 SyNergy), the
Clinical Competence Network for Multiple Sclerosis, the Werner
Reichenberger Stiftung, and the Verein zur Therapieforschung
für Multiple Sklerose-Kranke and by grants (to DJ) from
the European Union’s Horizon 2020 Research and Innovation
Program (668036, RELENT). Responsibility for the information
and views set out in this article lies entirely with the authors.
AV was supported by post-doctoral fellowships from European
Academy of Neurology, TÜBI˙TAK-BIDEB 2219 program and
Alexander von Humboldt Foundation Georg Forster Research
Fellowship Program during this project.
ACKNOWLEDGMENTS
We are grateful to Heike Rübsamen for expert technical
assistance and to Drs. Stefanie Hauck and Klaus Dornmair
for valuable support. We thank Drs. Anneli Peters and Naoto
Kawakami for comments on the manuscript.
REFERENCES
1. O’Connor KC., McLaughlin KA., De Jager PL., Chitnis T, Bettelli E, Xu C,
et al. Wucherpfennig: Self-antigen tetramers discriminate between myelin
autoantibodies to native or denatured protein. Nat Med. (2007) 13:211–
7. doi: 10.1038/nm1488
2. Brilot F, Dale RC, Selter RC, Grummel V, Kalluri SR, Aslam M, et al.
Antibodies to native myelin oligodendrocyte glycoprotein in children with
inflammatory demyelinating central nervous system disease. Ann Neurol.
(2009) 66:833–42. doi: 10.1002/ana.21916
3. Pröbstel AK, Dornmair K, Bittner R, Sperl P, Jenne D, Magalhaes
S, et al. Antibodies to MOG are transient in childhood acute
disseminated encephalomyelitis. Neurology. (2011) 77:580–
8. doi: 10.1212/WNL.0b013e318228c0b1
4. Peschl P, Bradl M, Hoftberger R, Berger T, Reindl M. Myelin oligodendrocyte
glycoprotein: deciphering a target in inflammatory demyelinating diseases.
Front Immunol. (2017) 8:529. doi: 10.3389/fimmu.2017.00529
5. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-
IgG in NMO and related disorders: a multicenter study of 50 patients. Part
2: epidemiology, clinical presentation, radiological and laboratory features,
treatment responses, and long-term outcome. J Neuroinflammation. (2016)
13:280. doi: 10.1186/s12974-016-0718-0
6. Ramanathan S, Dale RC, Brilot F. Anti-MOG antibody: the history, clinical
phenotype, and pathogenicity of a serum biomarker for demyelination.
Autoimmun Rev. (2016) 15:307–24. doi: 10.1016/j.autrev.2015.12.004
7. Hohlfeld R, Dornmair K, Meinl E, Wekerle H. The search for the target
antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies
in the focus of reverse-translational research. Lancet Neurol. (2016) 15:317–
31. doi: 10.1016/S1474-4422(15)00313-0
8. Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca-Fernandez
A, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK
study. Brain. (2017) 140:3128–38. doi: 10.1093/brain/awx276
9. Mayer MC, Meinl E. Glycoproteins as targets of autoantibodies in CNS
inflammation: MOG and more. Ther Adv Neurol Disord. (2012) 5:147–
59. doi: 10.1177/1756285611433772
10. Reindl M, Waters P. Myelin oligodendrocyte glycoprotein
antibodies in neurological disease. Nat Rev Neurol. (2018)
15:89–102. doi: 10.1038/s41582-018-0112-x
11. Di Pauli F, Berger T. Myelin oligodendrocyte glycoprotein antibody-
associated disorders: toward a new spectrum of inflammatory demyelinating
CNS disorders? Front Immunol. (2018) 9:2753. doi: 10.3389/fimmu.2018.
02753
12. Mader S, Gredler V, Schanda K, Rostasy K, Dujmovic I, Pfaller K, et al.
Complement activating antibodies to myelin oligodendrocyte glycoprotein
in neuromyelitis optica and related disorders. J.Neuroinflammation. (2011)
8:184. doi: 10.1186/1742-2094-8-184
13. Dale RC, Tantsis EM, Merheb V, Kumaran RY, Sinmaz N, Pathmanandavel
K, et al. Antibodies to MOG have a demyelination phenotype and affect
oligodendrocyte cytoskeleton. Neurol Neuroimmunol Neuroinflamm. (2014)
1:e12. doi: 10.1212/NXI.0000000000000012
14. Peschl P, Schanda K, Zeka B, Given K, Bohm D, Ruprecht K, et al.
Human antibodies against the myelin oligodendrocyte glycoprotein can
cause complement-dependent demyelination. J Neuroinflammation. (2017)
14:208. doi: 10.1186/s12974-017-0984-5
15. Kinzel S, Lehmann-Horn K, Torke S, Hausler D, Winkler A, Stadelmann C,
et al. Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune
disease by opsonization of endogenous antigen. Acta Neuropathol. (2016)
132:43–58. doi: 10.1007/s00401-016-1559-8
16. Zhou D, Srivastava R, Nessler S, Grummel V, Sommer N, Bruck W,
et al. Identification of a pathogenic antibody response to native myelin
oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci USA.
(2006) 103:19057–62. doi: 10.1073/pnas.0607242103
17. Saadoun S, Waters P, Owens GP, Bennett JL, Vincent A, Papadopoulos MC.
Neuromyelitis opticaMOG-IgG causes reversible lesions in mouse brain.Acta
Neuropathol Commun. (2014) 2:35. doi: 10.1186/2051-5960-2-35
18. Flach AC, Litke T, Strauss J, Haberl M, Gomez CC, Reindl M, et al.
Autoantibody-boosted T-cell reactivation in the target organ triggers
manifestation of autoimmune CNS disease. Proc Natl Acad Sci USA. (2016)
113:3323–28. doi: 10.1073/pnas.1519608113
19. Khare P, Challa DK, Devanaboyina SC, Velmurugan R, Hughes S, Greenberg
BM, et al. Myelin oligodendrocyte glycoprotein-specific antibodies from
multiple sclerosis patients exacerbate disease in a humanized mouse model.
J Autoimmun. (2018) 86:104–15. doi: 10.1016/j.jaut.2017.09.002
20. Spadaro M, Winklmeier S, Beltran E, Macrini C, Hoftberger R, Schuh E,
et al. Pathogenicity of human antibodies against myelin oligodendrocyte
glycoprotein. Ann Neurol. (2018) 84:315–28. doi: 10.1002/ana.25291
21. Clements CS, Reid HH, Beddoe T, Tynan FE, Perugini MA, Johns TG,
et al. The crystal structure of myelin oligodendrocyte glycoprotein, a key
autoantigen in multiple sclerosis. Proc Natl Acad Sci USA. (2003) 100:11059–
64. doi: 10.1073/pnas.1833158100
Frontiers in Immunology | www.frontiersin.org 9 June 2019 | Volume 10 | Article 1189
Marti Fernandez et al. MOG-Glycosylation Site Affects Ab Recognition
22. Breithaupt C, Schubart A, Zander H, Skerra A, Huber R, Linington
C, et al. Structural insights into the antigenicity of myelin
oligodendrocyte glycoprotein. Proc Natl Acad Sci USA. (2003)
100:9446–51. doi: 10.1073/pnas.1133443100
23. Mayer MC, Breithaupt C, Reindl M, Schanda K, Rostasy K, Berger T,
et al. Distinction and temporal stability of conformational epitopes on
myelin oligodendrocyte glycoprotein recognized by patients with different
inflammatory central nervous system diseases. J Immunol. (2013) 191:3594–
604. doi: 10.4049/jimmunol.1301296
24. Breithaupt C, Schafer B, Pellkofer H, Huber R, Linington C, Jacob U.
Demyelinating myelin oligodendrocyte glycoprotein-specific autoantibody
response is focused on one dominant conformational epitope region
in rodents. J Immunol. (2008) 181:1255–63. doi: 10.4049/jimmunol.181.
2.1255
25. Labasque M, Hivert B, Nogales-Gadea G, Querol L, Illa I, Faivre-Sarrailh
C. Specific contactin N-glycans are implicated in neurofascin binding and
autoimmune targeting in peripheral neuropathies. J Biol Chem. (2014)
289:7907–18. doi: 10.1074/jbc.M113.528489
26. Reitter JN, Means RE, Desrosiers RC. A role for carbohydrates in immune
evasion in AIDS. Nat Med. (1998) 4:679–84. doi: 10.1038/nm0698-679
27. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al.
Antibody neutralization and escape by HIV-1. Nature. (2003) 422:307–
12. doi: 10.1038/nature01470
28. Falkowska E, Le KM, Ramos A, Doores KJ, Lee JH, Blattner C, et al.
Broadly neutralizing HIV antibodies define a glycan-dependent epitope on
the prefusion conformation of gp41 on cleaved envelope trimers. Immunity.
(2014) 40:657–68. doi: 10.1016/j.immuni.2014.04.009
29. Spadaro M, Gerdes LA, Mayer MC, Ertl-Wagner B, Laurent S,
Krumbholz M, et al. Histopathology and clinical course of MOG-
antibody associated encephalomyelitis. Ann Clin Transl Neurol. (2015)
2:295–301. doi: 10.1002/acn3.164
30. Waters P, Woodhall M, O’Connor KC, Reindl M, Lang B, Sato DK,
et al. MOG cell-based assay detects non-MS patients with inflammatory
neurologic disease. Neurol Neuroimmunol Neuroinflamm. (2015)
2:e89. doi: 10.1212/NXI.0000000000000089
31. Lopez-Chiriboga AS, Majed M, Fryer J, Dubey D, McKeon A,
Flanagan EP, et al. Association of MOG-IgG serostatus with relapse
after acute disseminated encephalomyelitis and proposed diagnostic
criteria for MOG-IgG-associated disorders. JAMA Neurol. (2018)
75:1355–63. doi: 10.1001/jamaneurol.2018.1814
32. Ramanathan S, Reddel SW, Henderson A, Parratt JD, Barnett M, Gatt
PN, et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral
and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm. (2014)
1:e40. doi: 10.1212/NXI.0000000000000040
33. Kaneko K, Sato DK, Nakashima I, Ogawa R, Akaishi T, Takai Y, et al. CSF
cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-
IgG+ NMOSD but distinct from MS: a cross-sectional study and potential
therapeutic implications. J Neurol Neurosurg Psychiatry. (2018) 89:927–
36. doi: 10.1136/jnnp-2018-317969
34. Spadaro M, Gerdes LA, Krumbholz M, Ertl-Wagner B, Thaler FS,
Schuh E, et al. Autoantibodies to MOG in a distinct subgroup of
adult multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. (2016)
3:e257. doi: 10.1212/NXI.0000000000000257
35. Zamvil SS, Slavin AJ. Does MOG Ig-positive AQP4-seronegative
opticospinal inflammatory disease justify a diagnosis of NMO
spectrum disorder? Neurol Neuroimmunol Neuroinflamm. (2015)
2:e62. doi: 10.1212/NXI.0000000000000062
36. Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, et al. MOG
encephalomyelitis: international recommendations on diagnosis and antibody
testing. J Neuroinflammation. (2018) 15:134. doi: 10.1186/s12974-018-
1144-2
37. Brändle SM, Obermeier B, Senel M, Bruder J, Mentele R, Khademi M,
et al. Distinct oligoclonal band antibodies in multiple sclerosis recognize
ubiquitous self-proteins. Proc Natl Acad Sci USA. (2016) 113:7864–
9. doi: 10.1073/pnas.1522730113
38. Perera NC, Wiesmuller KH, Larsen MT, Schacher B, Eickholz P, Borregaard
N, et al. NSP4 is stored in azurophil granules and released by activated
neutrophils as active endoprotease with restricted specificity. J Immunol.
(2013) 191:2700–7. doi: 10.4049/jimmunol.1301293
39. Royle L, Radcliffe CM, Dwek RA, Rudd PM. Detailed structural analysis of
N-glycans released from glycoproteins in SDS-PAGE gel bands using HPLC
combined with exoglycosidase array digestions. Methods Mol Biol. (2006)
347:125–43. doi: 10.1385/1-59745-167-3:125
40. Reiding KR, Blank D, Kuijper DM, Deelder AM, Wuhrer M. High-
throughput profiling of protein N-glycosylation by MALDI-TOF-MS
employing linkage-specific sialic acid esterification. Anal Chem. (2014)
86:5784–93. doi: 10.1021/ac500335t
41. Ruhaak LR, Huhn C, Waterreus WJ, de Boer AR, Neususs C, Hokke
CH, et al. Hydrophilic interaction chromatography-based high-throughput
sample preparation method for N-glycan analysis from total human plasma
glycoproteins. Anal Chem. (2008) 80:6119–26. doi: 10.1021/ac800630x
42. Selman MH, Hemayatkar M, Deelder AM, Wuhrer M. Cotton HILIC
SPE microtips for microscale purification and enrichment of glycans and
glycopeptides. Anal Chem. (2011) 83:2492–9. doi: 10.1021/ac1027116
43. Jansen BC, Reiding KR, Bondt A, Hipgrave Ederveen AL, Palmblad
M, Falck D, et al. Massy tools: a high-throughput targeted data
processing tool for relative quantitation and quality control developed
for glycomic and glycoproteomic MALDI-MS. J Proteome Res. (2015)
14:5088–98. doi: 10.1021/acs.jproteome.5b00658
44. Malik R, Dau T, Gonik M, Sivakumar A, Deredge DJ, Edeleva
EV, et al. Common coding variant in SERPINA1 increases the
risk for large artery stroke. Proc Natl Acad Sci USA. (2017)
114:3613–8. doi: 10.1073/pnas.1616301114
45. Bournazos S, Wang TT, Dahan R, Maamary J, Ravetch JV. Signaling
by antibodies: recent progress. Annu Rev Immunol. (2017) 35:285–
311. doi: 10.1146/annurev-immunol-051116-052433
46. Dekkers G, Treffers L, Plomp R, Bentlage AEH, de Boer M, Koeleman CAM,
et al. Decoding the human immunoglobulin G-glycan repertoire reveals a
spectrum of Fc-receptor- and complement-mediated-effector activities. Front
Immunol. (2017) 8:877. doi: 10.3389/fimmu.2017.00877
47. Seeling M, Bruckner C, Nimmerjahn F. Differential antibody glycosylation
in autoimmunity: sweet biomarker or modulator of disease activity? Nat Rev
Rheumatol. (2017) 13:621–30. doi: 10.1038/nrrheum.2017.146
48. Wuhrer M, Selman MH, McDonnell LA, Kumpfel T, Derfuss T,
Khademi M, et al. Pro-inflammatory pattern of IgG1 Fc glycosylation
in multiple sclerosis cerebrospinal fluid. J Neuroinflammation. (2015)
12:235. doi: 10.1186/s12974-015-0450-1
49. van de Bovenkamp FS, Hafkenscheid L, Rispens T, Rombouts Y. The
emerging importance of IgG fab glycosylation in immunity. J Immunol. (2016)
196:1435–41. doi: 10.4049/jimmunol.1502136
50. Garcia-Vallejo JJ, Ilarregui JM, Kalay H, Chamorro S, Koning N, Unger
WW, et al. CNSmyelin induces regulatory functions of DC-SIGN-expressing,
antigen-presenting cells via cognate interaction with MOG. J Exp Med. (2014)
211:1465–83. doi: 10.1084/jem.20122192
51. Macauley MS, Crocker PR, Paulson JC. Siglec-mediated regulation of
immune cell function in disease. Nat Rev Immunol. (2014) 14:653–
66. doi: 10.1038/nri3737
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Marti Fernandez, Macrini, Krumbholz, Hensbergen, Hipgrave
Ederveen, Winklmeier, Vural, Kurne, Jenne, Kamp, Gerdes, Hohlfeld, Wuhrer,
Kümpfel and Meinl. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org 10 June 2019 | Volume 10 | Article 1189
